In the published article, there was an error in Figure 1 as published. The dose of IVIG was listed as 2 mg/kg over 2–5 days, when it should be 2 g/kg over 2–5 days.
Figure 1
Flow diagram for evaluation and management of NORSE/FIRES. NORSE, New Onset Refractory Status Epilepticus; FIRES, Febrile infection-related epilepsy syndrome; SE, Status epilepticus; RSE, Refractory status epilepticus; GAD, Gadolinium; MRV, Magnetic resonance venogram; MRA, Magnetic resonance angiography; CEEG, Continuous EEG; USG, Ultrasonography; PET, Positron emission tomography; HSV, Herpes simplex virus; VNS, Vagus nerve stimulator. 
Diagnostic consideration. 
Diagnostic procedure. 
Treatment. 
Outcome assessment. 
Management timeline.
The corrected Figure 1 and its caption appear below.
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Statements
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Summary
Keywords
new-onset refractory status epilepticus, febrile infection related epilepsy syndrome, anakinra, tocilizumab, rituximab, super-refractory status epilepticus, neuroinflammation, autoimmune encephalitis
Citation
Sheikh Z and Hirsch LJ (2024) Corrigendum: A practical approach to in-hospital management of new-onset refractory status epilepticus/febrile infection related epilepsy syndrome. Front. Neurol. 15:1509148. doi: 10.3389/fneur.2024.1509148
Received
10 October 2024
Accepted
15 October 2024
Published
11 November 2024
Volume
15 - 2024
Edited and reviewed by
Aljoscha Thomschewski, University Hospital Salzburg, Austria
Updates
Copyright
© 2024 Sheikh and Hirsch.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Zubeda Sheikh zubeda.sheikh@vcuhealth.orgLawrence J. Hirsch lawrence.hirsch@yale.edu
†Present address: Zubeda Sheikh, Department of Neurology, Virginia Commonwealth University, Richmond, VA, United States
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.